• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Galapagos NV

    10/8/24 4:35:06 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLPG alert in real time by email
    SC 13D/A 1 tm2425722d1_sc13da.htm SC 13D/A

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D/A

    (Amendment No. 1)*

    (Rule 13d-101)

     

    Information to be included in statements filed pursuant

    to § 240.13d-1(a) and amendments thereto filed

    pursuant to § 240.13d-2(a)

    Under the Securities Exchange Act of 1934

     

    Galapagos NV

    (Name of Issuer)

     

    Ordinary Shares, no par value

    (Title of Class of Securities)

     

    36315X101

    (CUSIP Number)

     

    Oleg Nodelman

    EcoR1 Capital, LLC

    357 Tehama Street #3

    San Francisco, CA 94103

    (415) 448-6534

     

    with a copy to

     

    Richard M. Brand

    Cadwalader, Wickersham & Taft LLP

    200 Liberty Street

    New York, NY 10281

    (212) 504-6000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    October 6, 2024

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

      1.

    Names of Reporting Persons

    EcoR1 Capital, LLC

      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) x
      3. SEC Use Only
      4.

    Source of Funds (See Instructions)

    AF

      5. Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) o
      6.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    7,094,0491

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    7,094,0491

      11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    7,094,0491

      12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) o
      13.

    Percent of Class Represented by Amount in Row (11)

    10.77%*

      14.

    Type of Reporting Person (See Instructions)

    OO, IA

                      

    1 The amounts reported include (1) ordinary shares, no par value, of Galapagos NV (the “Issuer”) and (2) American Depositary Shares, each of which represents one ordinary share, no par value, of the Issuer.

    * All percentage calculations set forth herein are based on 65,897,071 ordinary shares, no par value, of the Issuer issued and outstanding as of December 31, 2023, as reported in the Issuer’s Form 20-F filed with the U.S. Securities and Exchange Commission on March 28, 2024 (the “Form 20-F”). 

     

     

     

     

      1.

    Names of Reporting Persons

    Oleg Nodelman

      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) x
      3. SEC Use Only
      4.

    Source of Funds (See Instructions)

    AF

      5. Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) o
      6.

    Citizenship or Place of Organization

    United States of America

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    7,094,0491

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    7,094,0491

      11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    7,094,0491

      12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) o
      13.

    Percent of Class Represented by Amount in Row (11)

    10.77%*

      14.

    Type of Reporting Person (See Instructions)

    IN

                      

    1 The amounts reported above include (1) ordinary shares, no par value, of the Issuer and (2) American Depositary Shares, each of which represents one ordinary share, no par value, of the Issuer.

    * All percentage calculations set forth herein are based on 65,897,071 ordinary shares, no par value, of the Issuer issued and outstanding as of December 31, 2023, as reported in the Form 20-F.

     

     

     

     

      1.

    Names of Reporting Persons

    EcoR1 Capital Fund Qualified, L.P.

      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) x
      3. SEC Use Only
      4.

    Source of Funds (See Instructions)

    WC

      5. Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) o
      6.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    6,674,7381

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    6,674,7381

      11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    6,674,7381

      12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) o
      13.

    Percent of Class Represented by Amount in Row (11)

    10.13%*

      14.

    Type of Reporting Person (See Instructions)

    PN

                      

    1 The amounts reported above include (1) ordinary shares, no par value, of the Issuer and (2) American Depositary Shares, each of which represents one ordinary share of the Issuer.

    * All percentage calculations set forth herein are based on 65,897,071 ordinary shares, no par value, of the Issuer issued and outstanding as of December 31, 2023, as reported in the Form 20-F.

     

     

     

     

      1.

    Names of Reporting Persons

    EcoR1 Capital Fund L.P.

      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) x
      3. SEC Use Only
      4.

    Source of Funds (See Instructions)

    WC

      5. Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) o
      6.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    419,3111

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    419,3111

      11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    419,3111

      12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) o
      13.

    Percent of Class Represented by Amount in Row (11)

    0.64%*

      14.

    Type of Reporting Person (See Instructions)

    PN

                        

    1 The amounts reported above include (1) ordinary shares, no par value, of the Issuer and (2) American Depositary Shares, each of which represents one ordinary share of the Issuer.

    * All percentage calculations set forth herein are based on 65,897,071 ordinary shares, no par value, of the Issuer issued and outstanding as of December 31, 2023, as reported in the Form 20-F.

     

     

     

     

    Explanatory Note

     

    This Amendment No. 1 to Schedule 13D (“Amendment No. 1”) amends and supplements the Schedule 13D filed on August 23, 2024 to the extent set forth herein (as amended and supplemented through the date of this Amendment No. 1, collectively, the “Schedule 13D”) by the Reporting Persons, relating to the ordinary shares, no par value (the “Ordinary Shares”), and American Depositary Shares, each of which represents one ordinary share, no par value (the “ADSs”), of the Issuer (together, the “Shares”). Capitalized terms not otherwise defined in this Amendment No. 1 shall have the meaning ascribed to them in the Schedule 13D.

     

    Item 3.

    Source and Amount of Funds or Other Consideration.

     

    Item 3 of the Schedule 13D is hereby amended and restated in its entirety as follows:

     

    All of the Shares reported herein were purchased by the Funds for an aggregate purchase price of $353,195,707.22 including fees and expenses, excluding fees with respect to the conversion of ADSs to Ordinary Shares. In connection with the surrender of certain ADSs held by the Funds and withdrawal of ordinary shares of the Issuer from Citibank, N.A., as depositary (the “Depositary” and such exchange, the “ADS Conversion”), the Funds paid $293,693.40 in fees to the Depositary. The source of funds used by the Funds to purchase such Shares and to effect the ADS Conversion was derived from the capital of the Funds.

     

    The response to Item 5 of the Schedule 13D is incorporated herein by reference. Unless noted above, no part of the purchase price for such Shares was borrowed by any Reporting Person for the purpose of acquiring, holding, trading or voting any securities discussed in this Item 3.

     

    Item 4.   Purpose of Transaction.

     

    Item 4 of the Schedule 13D is hereby amended and supplemented to add the following information to the end thereof:

     

    On October 6, 2024, the Board agreed to appoint Mr. Nodelman to the Board as a non-executive non-independent director, effective October 7, 2024, and to nominate and recommend Mr. Nodelman for appointment as director with a term of four years at the next meeting of shareholders of the Issuer.

     

    The response to Item 5 of the Schedule 13D is incorporated herein by reference.

     

    Item 5. Interest in Securities of the Issuer.

     

    Items 5(a), (b) and (c) of the Schedule 13D are hereby amended and restated in their entirety as follows:

     

    (a), (b) EcoR1 and Mr. Nodelman each may be deemed to beneficially own an aggregate of 7,094,049 Shares (the “Subject Shares”), representing approximately 10.77% of the outstanding Shares based on 65,897,071 Shares outstanding as of December 31, 2023, as reported in the Issuer’s Form 20-F. Qualified Fund may be deemed to beneficially own an aggregate of 6,674,738 of the Subject Shares, representing approximately 10.13% of the outstanding Shares. Capital Fund may be deemed to beneficially own an aggregate of 419,311 of the Subject Shares, representing approximately 0.64% of the outstanding Shares.

     

    EcoR1, as the general partner of each of the Funds, may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all the Subject Shares. Mr. Nodelman may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all the Subject Shares. Each of the Funds may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) only the Subject Shares that it beneficially owns.

     

     

     

     

    (c) Exhibit 99.2 filed herewith, which is incorporated by reference into this Item 5(c), describes the transactions in the Shares that were effected by the Reporting Persons since the Reporting Persons’ most recent filing on Schedule 13D.

     

     Pursuant to the terms of the Depositary Agreement dated May 4, 2015, between the Issuer and the Depositary, on September 10, 2024, EcoR1 caused the Funds to begin the ADS Conversion, pursuant to which Qualified Fund surrendered 5,526,088 ADSs to the Depositary and received in exchange 5,526,088 Ordinary Shares, and Capital Fund surrendered 347,780 ADSs to the Depositary and received in exchange 347,780 Ordinary Shares. The ADS Conversion exchange was completed on September 20, 2024.

     

    Except as set forth in Exhibit 99.2 filed herewith and other than the ADS Conversion, no transactions in the Shares were effected by the Reporting Persons since the Reporting Persons’ most recent filing on Schedule 13D.

     

    Item 7. Material to be Filed as Exhibits.

      

    Item 7 is hereby amended and supplemented to add the following exhibits:

     

    Exhibit 99.2Trading Data.

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: October 8, 2024 EcoR1 CAPITAL, LLC
       
      By: /s/ Oleg Nodelman
        Name: Oleg Nodelman
        Title: Manager
       
    Date: October 8, 2024 OLEG NODELMAN
       
      By: /s/ Oleg Nodelman
        Oleg Nodelman
       
    Date: October 8, 2024 EcoR1 CAPITAL FUND QUALIFIED, L.P.
       
      By: EcoR1 Capital, LLC, General Partner
       
      By: /s/ Oleg Nodelman
        Name: Oleg Nodelman
        Title: Manager
       
    Date: October 8, 2024 EcoR1 CAPITAL FUND, L.P.
       
      By: EcoR1 Capital, LLC, General Partner
       
      By: /s/ Oleg Nodelman
        Name: Oleg Nodelman
        Title: Manager

     

     

    Get the next $GLPG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GLPG

    DatePrice TargetRatingAnalyst
    10/22/2025$40.00Market Perform → Outperform
    Leerink Partners
    8/5/2025Hold → Sell
    Deutsche Bank
    2/14/2025$31.00 → $22.00Equal-Weight → Underweight
    Morgan Stanley
    11/20/2024Hold → Reduce
    Kepler
    9/9/2024$24.00Market Perform
    Leerink Partners
    8/2/2024Outperform → Mkt Perform
    Raymond James
    3/28/2024$41.00 → $31.00Neutral → Underperform
    BofA Securities
    3/7/2024$38.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $GLPG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update

    Galapagos' name change to Lakefront Biotherapeutics approved at the Company's EGM ((Euronext &, NASDAQ:LKFT)Collaboration Agreement with Gilead to advance potential First and Best-in-Class T Cell Engager expected to close in the Second Quarter of 2026Following this transaction, including estimated associated R&D spend until first approval, the Company will continue to have a majority of its current cash remaining for additional strategic transactions and other capital allocation prioritiesYear-end 2026 cash and financial investments balance expected to be approximately €2BManagement to host conference call on May 7, 2026, at 14:00 CET / 8:00 am ETMechelen, Belgium; May 6, 2026, 22:01 CET; re

    5/6/26 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos' Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders' Meetings 2026

    Mechelen, Belgium; April 28, 2026, 22:01 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG) today announces that all resolutions proposed at the Company's Annual and Extraordinary Shareholders' Meetings (AGM and EGM) held on 28 April 2026 were approved. The AGM approved, amongst other items: The Annual Report and the Remuneration ReportThe remuneration of the members of the Board of DirectorsThe appointment of Mr. Henry Gosebruch as Executive DirectorThe appointments of Dr. Jane Griffiths, Ms. Dawn Svoronos, Dr. Neil Johnston, Dr. Paulo Fontoura, and Mr. Gino Santini as Independent Non-Executive Directors and Mr. Devang Bhuva as Non-Executive DirectorThe re-appointment of the statutory auditor

    4/28/26 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases

    New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos  Following this transaction, the Company will continue to have a majority of its cash remaining for additional strategic transactions and other capital allocation priorities Opportunity to develop a potential first-in-class & best-in-class T cell engager in autoimmune diseases with gamgertamig Management to host conference call today, March 31, 2026, at 14:00 CET / 8:00 am ET Mechelen, Belgium; March 31, 2026, 7.30 CET; regulated information – Announcement in application of Article 7:97, §4/1 of the BCCA — Galapagos NV ((Euronext &, NASDAQ:GLPG) ("Galapagos" or the "Company") today an

    3/31/26 1:30:00 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Galapagos NV upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Galapagos NV from Market Perform to Outperform and set a new price target of $40.00

    10/22/25 7:00:32 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos NV downgraded by Deutsche Bank

    Deutsche Bank downgraded Galapagos NV from Hold to Sell

    8/5/25 3:22:16 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos NV downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Galapagos NV from Equal-Weight to Underweight and set a new price target of $22.00 from $31.00 previously

    2/14/25 8:06:36 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    SEC Filings

    View All

    SEC Form 6-K filed by Galapagos NV

    6-K - Lakefront Biotherapeutics NV (0001421876) (Filer)

    5/27/26 6:00:09 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Galapagos NV

    424B3 - Lakefront Biotherapeutics NV (0001421876) (Filer)

    5/8/26 4:20:51 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Galapagos NV

    6-K - GALAPAGOS NV (0001421876) (Filer)

    5/6/26 5:19:16 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Leadership Updates

    Live Leadership Updates

    View All

    Galapagos' Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders' Meetings 2026

    Mechelen, Belgium; April 28, 2026, 22:01 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG) today announces that all resolutions proposed at the Company's Annual and Extraordinary Shareholders' Meetings (AGM and EGM) held on 28 April 2026 were approved. The AGM approved, amongst other items: The Annual Report and the Remuneration ReportThe remuneration of the members of the Board of DirectorsThe appointment of Mr. Henry Gosebruch as Executive DirectorThe appointments of Dr. Jane Griffiths, Ms. Dawn Svoronos, Dr. Neil Johnston, Dr. Paulo Fontoura, and Mr. Gino Santini as Independent Non-Executive Directors and Mr. Devang Bhuva as Non-Executive DirectorThe re-appointment of the statutory auditor

    4/28/26 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Announces Nomination of Gino Santini to its Board of Directors

    Subject to his election by shareholders, the Board intends to appoint Mr. Santini as Chair, succeeding Jérôme Contamine  Mr. Santini will bring extensive corporate governance, business development and industry leadership experience to the Board Mechelen, Belgium; March 26, 2026, 21:02 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG), today announced the proposed appointment of Gino Santini as a Non-Executive Independent Director, with the intention to appoint him as Chair of its Board of Directors, subject to shareholder approval at the Annual Shareholders' Meeting (AGM) on April 28, 2026. If elected, Gino Santini will replace current Director and Chair Jérôme Contamine, whose mandate as a m

    3/26/26 4:02:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders' Meetings

    Mechelen, Belgium; March 26, 2026, 21:01 CET; regulated information — Galapagos NV ((Euronext &, NASDAQ:GLPG) today published its annual report for the financial year 2025 and announced that its Annual Shareholders' Meeting (AGM) and an Extraordinary Shareholders' Meeting (EGM) will be held sequentially on Tuesday, April 28, 2026 at 14:00 CET and 15:00 CET at Schaliënhoevedreef 20T, 2800 Mechelen, Belgium. The annual report for the financial year 2025, including a review of figures and performance, is available online at https://www.glpg.com/financial-reports and can also be downloaded as PDF. The annual 2025 Form 20-F filing with the SEC is available at www.sec.gov/edgar. Galapagos has t

    3/26/26 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Financials

    Live finance-specific insights

    View All

    Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update

    Galapagos' name change to Lakefront Biotherapeutics approved at the Company's EGM ((Euronext &, NASDAQ:LKFT)Collaboration Agreement with Gilead to advance potential First and Best-in-Class T Cell Engager expected to close in the Second Quarter of 2026Following this transaction, including estimated associated R&D spend until first approval, the Company will continue to have a majority of its current cash remaining for additional strategic transactions and other capital allocation prioritiesYear-end 2026 cash and financial investments balance expected to be approximately €2BManagement to host conference call on May 7, 2026, at 14:00 CET / 8:00 am ETMechelen, Belgium; May 6, 2026, 22:01 CET; re

    5/6/26 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases

    New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos  Following this transaction, the Company will continue to have a majority of its cash remaining for additional strategic transactions and other capital allocation priorities Opportunity to develop a potential first-in-class & best-in-class T cell engager in autoimmune diseases with gamgertamig Management to host conference call today, March 31, 2026, at 14:00 CET / 8:00 am ET Mechelen, Belgium; March 31, 2026, 7.30 CET; regulated information – Announcement in application of Article 7:97, §4/1 of the BCCA — Galapagos NV ((Euronext &, NASDAQ:GLPG) ("Galapagos" or the "Company") today an

    3/31/26 1:30:00 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases

    Galapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro Medicines New partnership structure would achieve meaningfully improved financial terms and flexibility for Galapagos Following this potential transaction, the Company will continue to have a majority of its capital available for additional strategic transactions and other capital allocation priorities   Mechelen, Belgium; March 23, 2026, 23:02 CET; regulated information – inside information — Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that, following Gilead's entering into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focuse

    3/23/26 6:25:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Galapagos NV

    SC 13G/A - GALAPAGOS NV (0001421876) (Subject)

    11/12/24 9:55:16 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Galapagos NV

    SC 13D/A - GALAPAGOS NV (0001421876) (Subject)

    10/8/24 4:35:06 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Galapagos NV

    SC 13D - GALAPAGOS NV (0001421876) (Subject)

    8/23/24 4:01:26 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care